References
- Mazzaglia G, Straus SMJ, Arlett P, et al. Study design and evaluation of risk minimization measures: a review of studies submitted to the European medicines agency for cardiovascular, endocrinology, and metabolic drugs. Drug Saf. 2018;41:191–202.
- Harish S, Bhuvana K, Bengalorkar GM, et al. Flupirtine: clinical pharmacology. J Anaesthesiol Clin Pharmacol. 2012;28:172–177.
- European Medicines Agency: EMA/404308/2013. Assessment report for flupirtine containing medicinal products [Internet]. 2013 [cited 2017 Sep 24]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Flupirtine-containing_medicines/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500146103.pdf
- Nair AS. Flupirtine: a less-explored, neglected nonopioid analgesic. Anesth Analg. 2018;126:1425.
- Kaplan S, Ehlken B, Hamann X. Drug utilization patterns of flupirtine following implementation of risk minimization measures in Germany. Curr Med Res Opin. [cited 2019 Mar 13]; [7 p.]. DOI:10.1080/03007995.2019.1594743
- Varga Z, Sabzwari SRA, Vargova V. Cardiovascular risk of nonsteroidal anti-inflammatory drugs: an under-recognized public health issue. Cureus. 2017;9:e1144.